Framingham's SCIEX inks commercialization deal
SCIEX, a global life sciences and analytical technologies company based in Framingham, has announced that a novel form of cancer research technology from the company will be more commercially available through a deal with the Fred Hutchinson Cancer Research Center in Seattle, Wash.
SCIEX said the deal will enhance and make more reproducible a method known as Targeted Proteomics, which was named “Method of the Year” in 2013 by the life sciences journal Nature Methods. This method combines the features of immunoassays and mass spectrometry, two chemistry methods used in cancer research, and will result in commercially available technology that can measure proteins involved in cancer signaling pathways, according to SCIEX.
SCIEX’s Dr. Christie Hunter was awarded the Human Proteome Organization’s 2013 Science and Technology Award for her contributions to developing and commercializing the technology.
Now, SCIEX has acquired the rights to commercialize immune-MRM assays developed at the Paulovich Laboratory at the Fred Hutchinson center, known informally as Fred Hutch, to enhance the reach of the Targeted Proteomics field.
Despite its promise, the field has struggled because of a lack of availability of off-the-shelf content for this technique, but both SCIEX and Fred Hutch see the new collaboration as a way to solve that problem.
The collaboration, according to a SCIEX statement, “will improve reproducibility and … drive actionable research.”
“The research reproducibility crisis has been well-documented in the media recently, especially around antibody quality for immunoassays,” said Aaron Hudson, senior director of academic and clinical research business at SCIEX. “This collaboration will help to address this crisis.”
Image source: Freedigitalphotos.net
WBJ Web Partners
Most Recent
Most Recent
0 Comments